STOCK TITAN

Dr. Reddy’s (NYSE: RDY) shares audio of Dec 31, 2025 earnings call

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited filed a Form 6-K to share an audio recording of its earnings call for the quarter ended December 31, 2025. The call was conducted on January 21, 2026, and the company has provided a web link to the full audio recording for investors and exchanges.

The notice has been sent to the National Stock Exchange of India, BSE, New York Stock Exchange, and NSE IFSC, underscoring that this is a formal communication of the recorded earnings discussion for regulatory and investor information purposes.

Positive

  • None.

Negative

  • None.
 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

  

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934


January 2026


Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                                  Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  _____

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                  No  x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.


 


EXHIBITS

 

Exhibit
Number

 

Description of Exhibits

 

 

 

99.1


Intimation dated January 21, 2026

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

Date: January 21, 2026

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 

3

 

Exhibit 99.1


Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

January 21, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Sub: Audio Recording of the Earnings call conducted on January 21, 2026

 

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the link of the audio recording of the Earnings call for the quarter ended December 31, 2025, conducted on January 21, 2026.

 

Weblink: https://www.drreddys.com/cms/sites/default/files/2026-01/GMT20260121-140031_Recording.mp3

 

This is for your information and record.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

 

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR


FAQ

What does Dr. Reddy’s Laboratories (RDY) report in this Form 6-K?

The Form 6-K states that Dr. Reddy’s Laboratories Limited has made available an audio recording of its earnings call for the quarter ended December 31, 2025, held on January 21, 2026.

Which period’s results are discussed in Dr. Reddy’s (RDY) earnings call mentioned here?

The audio recording relates to the earnings call for the quarter ended December 31, 2025.

When was the Dr. Reddy’s (RDY) earnings call conducted?

The earnings call referenced in the filing was conducted on January 21, 2026.

Where can investors access the Dr. Reddy’s (RDY) earnings call audio recording?

The Form 6-K provides a weblink to the audio recording hosted on Dr. Reddy’s website at the specified URL in the notice.

Which stock exchanges received this earnings call intimation from Dr. Reddy’s (RDY)?

The intimation was sent to the National Stock Exchange of India, BSE Limited, the New York Stock Exchange, and NSE IFSC Ltd.

Who signed the Dr. Reddy’s (RDY) earnings call intimation?

The intimation was signed by K Randhir Singh, who is the Company Secretary, Compliance Officer & Head-CSR of Dr. Reddy’s Laboratories Limited.
Dr Reddys Labs

NYSE:RDY

RDY Rankings

RDY Latest News

RDY Latest SEC Filings

RDY Stock Data

11.41B
834.61M
13.54%
1.14%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad